Please try another search
ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company's portfolio is led by eblasakimab (ASLAN004), a human monoclonal antibody that binds to the IL-13 receptor α1 subunit (IL-13Rα1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13 which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. It is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy in autoimmune disease. It is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The Company is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.
Name | Age | Since | Title |
---|---|---|---|
Carl Alan Jason Morton Firth | 50 | 2010 | Founder, CEO & Executive Director |
Andrew Howden | 64 | 2016 | Independent Chairman |
Robert E. Hoffman | 57 | 2018 | Independent Non-Executive Director |
Lawrence F. Eichenfield | 64 | 2021 | Chairman of Scientific Advisory Board |
Kathleen M. Metters | 66 | 2021 | Independent Director |
Eric Simpson | - | 2021 | Member of Scientific Advisory Board |
Melinda Jennifer Gooderham | - | 2021 | Member of Scientific Advisory Board |
Neil Graham | 65 | 2021 | Independent Director |
Peter Foley | - | 2021 | Member of Scientific Advisory Board |
Reynold A. Panettieri | - | 2024 | Scientific Advisor |
Ramaswamy Krishnan | - | 2024 | Scientific Advisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review